Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Table 1

Characteristics of the 10 included studies.

Study (year)	E/C	Intervention	CKI dosage (ml/day)	Duration	Outcome measures
Duan P. 2009	72/71	CKI + GP vs. GP	20	NA	➀➁➂➃
Wang L. 2009	44/30	CKI + DP/GP vs. TP/GP	20	15–20 days/course, 2 courses	➀➁➂➃
Yuan X. R. 2010	53/56	CKI + GEM vs. GEM	20	4weeks/course, 4 courses	➀➁➂➃
Liu M. 2014	42/48	CKI + NP vs. NP	20	4 weeks/course, 4 courses	➂➃
Zhang J. J. 2015	42/42	CKI + TP vs. TP	20	3 weeks/course, 3 courses	➀➂
Zhang J. W. 2015	60/60	CKI + GP vs. GP	2	3 weeks/course, 2 courses	➀➁➂
Chen W. F. 2015	52/53	CKI + GP/GP/TP vs. GP/GP/TP	20	12 days/course, 2 course	➀➁➂➃
Zhang X. L. 2018	30/30	CKI + TEG vs. TEG	20	3 weeks/course, 4 courses	➀➃
Jia L. 2018	42/38	CKI + PP vs. PP	20	21 days/course, 1 course	➀➁➂➃
Zhang H. F. 2019	77/77	CKI + TP vs. TP	20	21 days/course, 2 courses	➀➁➃

Note. E: experimental group; C: control group; CKI: compound kushen injection; NA: not available; DP: docetaxel + cisplatin; GP: gemcitabine + cisplatin; GEM: gemcitabine; NP: navelbine + cisplatin; PP: pemetrexed + carboplatin; TP: Taxol + cisplatin; TEG: tegafur; ➀: clinical efficiency; ➁: Karnofsky performance score; ➂: immune function; ➃: adverse reaction.